Securities Class Actions – Page 52 – ClaimsFiler

Case Type: Securities Class Actions

According to the Complaint, Alpha and Omega Semiconductor Limited designs, develops, and supplies power semiconductors. It purports to have a portfolio of over 2,100 products that target high volume applications, including personal computers, LED lighting, battery packs, home appliances, and consumer and industrial motor controls.

According to the Complaint, Paysign, Inc. purports to provide prepaid card programs and processing services under the PaySign brand to corporations, government agencies, universities, and other organizations. The Company changed its name from 3PEA International Inc. to Paysign, Inc. on April 23, 2019.

According to the Complaint, TD Ameritrade provides investing services and education to approximately 12 million client accounts totaling approximately $1.3 trillion in assets, and custodial services to more than 7,000 registered investment advisors.

According to the Complaint, LogicBio Therapeutics, Inc. purports to be a genome editing company, focused on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The Company’s lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia (“MMA”), a life-threatening disease that presents at birth.

According to the Complaint, Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.

According to the Complaint, Forescout Technologies, Inc. delivers device visibility and control to enable enterprises and government agencies to gain complete situational awareness of their environment and orchestrate action.

According to the Complaint, Gulfport Energy Corporation engages in the exploration, development, acquisition, and production of natural gas, crude oil, and natural gas liquids in the U.S.

According to the Complaint, Norwegian Cruise Lines is a global cruise company which operates the Norwegian Cruise Line, Oceania Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises brands.

According to the Complaint, Inovio Pharmaceuticals, Inc. purports to be a "biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from . . . infectious diseases."

According to the Complaint, Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. Cronos seeks to invest in companies either licensed, or actively seeking a license, to producemedical marijuana pursuant to Canada’s Marihuana for Medical Purposes Regulations (MMPR). The Company typically invests in companies based in Canada.

According to the Complaint, Stein Mart, Inc. is a specialty offprice retailer, offers designer and name-brand fashion apparels, home décor merchandise, accessories, and shoes at everyday discount prices in the Unites States.

According to the Complaint, Allakos Inc. is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

According to the Complaint, Funko, Inc. is a pop culture consumer products company that creates figures, plush, accessories, apparel, and homewares regarding movies, TV shows, videogames, musicians, and sports teams.

According to the Complaint, NMC Health Plc, together with its subsidiaries, purports to provide healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The Company purports to own and manage approximately 200 healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The Company purports to offer medical services as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services to hospitals, as well as retail pharmaceutical goods.

According to the Complaint, PharmaCielo, through its subsidiary, PharmaCielo Colombia Holdings S.A.S., purports to cultivate, process, produce, and supply medicinal-grade cannabis oil extracts and related products in Colombia and internationally.

We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.

OK